王海燕,韩媛媛,孟凡华

• 1:济宁医学院附属医院心血管内科
• 2:山东省细胞生物医疗技术重点实验室
• 3:山东医药卫生心血管重点实验室

摘要(Abstract)：

DynamX生物适配系统作为冠状动脉介入治疗领域的一项创新，针对传统药物洗脱支架的局限性而研发，旨在通过其独特的“锁定-解锁/分离-适应性动态支撑”三阶段递进式作用机制，优化治疗策略并改善患者预后。通过有限元分析、人体在体试验及多中心临床试验，验证了DynamX生物适配系统在减少冠状动脉装置峰值应力、改善血管旋转运动、促进血管功能恢复方面的显著优势，特别是在降低靶病变失败率方面优于传统支架，尤其在复杂病变治疗中展现出巨大潜力。DynamX生物适配系统的出现不仅重新定义了血管介入治疗的标准，更为冠心病治疗提供了“主动修复”的新范式。未来随着长期安全性数据的积累、适应证扩展以及技术迭代，DynamX生物适配系统有望在更广泛的领域发挥重要作用，推动血管介入治疗向更加精准、个体化的方向发展。

关键词(KeyWords)： DynamX生物适配系统;冠状动脉介入治疗;药物洗脱支架;临床研究

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目（82570429）

作者(Author): 王海燕,韩媛媛,孟凡华

参考文献(References)：

• [1]Byrne RA,Stone GW,Ormiston J,et al.Coronary balloon angioplasty,stents,and scaff olds[J].Lancet,2017,390(10096):781-792.DOI:10.1016/S0140-6736(17)31927-X.
• [2]Choi KH,Song YB,Lee JM,et al.Dif ferential long-term ef fects of fi rst-and second-generation DES in patients with bifurcation lesions undergoing PCI[J].JACC Asia,2021,1(1):68-79. DOI:10.1016/j.jacasi.2021.04.006.
• [3]Visseren FLJ,Mach F,Smulders YM,et al.2021 ESC Guidelines on cardiovascular disease prevention in clinical practice[J].Eur Heart J,2021,42(34):3227-3337. DOI:10.1093/eurheartj/ehac458.
• [4]Moriyama N,Shishido K,Tanaka Y,et al.Neoatherosclerosislong-term assessment of bioresorbable vascular scaffold[J].Circ Rep,2019,1(12):543-549. DOI:10.1253/circrep.CR-19-0100.
• [5]Sakamoto N,Nakazato K,Misaka T,et al.Very late stent thrombosis and neointimal plaque rupture after implantation of sirolimuseluting stents:observations with angiography,IVUS and OCT[J].Cardiovasc Interv Ther,2011,26(3):263-268. DOI:10.1007/s12928-011-0064-1.
• [6]Serruys PW,Onuma Y,Garcia-Garcia HM,et al.Dynamics of vessel wall changes following the implantation of the absorb everolimuseluting bioresorbable vascular scaff old:a multi-imaging modality study at 6,12,24 and 36 months[J].EuroIntervention,2014,9(11):1271-1284. DOI:10.4244/EIJV9I11A217.
• [7]Montone RA,Brown AJ,Niccoli G.Bioresorbable vascular scaff olds:between promises and reality[J].Oncotarget,2017,8(41):69202-69203.DOI:10.18632/oncotarget.20630.
• [8]Kearney A,Linden K,Savage P,et al.Advances in clinical cardiology2020:a summary of key clinical trials[J].Adv Ther,2021,38(5):2170-2200. DOI:10.1007/s12325-021-01711-z.
• [9]Saito S,Nef HM,Webster M,et al.DynamX RCT investigators.DynamX sirolimus-eluting Bioadaptor versus the zotarolimuse luting Resolute Onyx stent in patients with de novo coronary artery lesions:design and rationale of the multicenter,international,randomized BIODAPTOR-RCT[J].Cardiovasc Revasc Med, 2023, 55:76-82. DOI:10.1016/j.carrev.2023.05.010.
• [10]Saito S,Bennett J,Nef HM,et al.First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimuseluting drug-eluting stent in patients with de novo coronary artery lesions:12-month clinical and imaging data from the multicentre,international,BIODAPTOR-RCT[J].EClinicalMedici ne,2023,65:102304. DOI:10.1016/j.eclinm.2023.102304.
• [11]Erlinge D,Andersson J,Fr??bert O,et al.Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden(INFINITY-SWEDEHEART):a singleblind,non-inferiority,registry-based,randomised controlled trial[J].Lancet,2024,404(10464):1750-1759. DOI:10.1016/S0140-6736(24)02227-X.
• [12]Kansal MM,Wolska B,Verheye S,et al.Adaptive coronary artery rotational motion through uncaging of a drug-eluting bioadaptor aiming to reduce stress on the coronary artery[J].Cardiovasc Revasc Med, 2022, 39:52-57. DOI:10.1016/j.carrev.2021.09.009.
• [13]Wong SF,Chow HC,Chan K,et al.The double bioadaptors culotte(ADAPT-CULOTTE)technique:from bench testing to the fi rst-in-human longitudinal imaging analysis[J].JACC Cardiovasc Interv,2024,17(24):2957-2960. DOI:10.1016/j.jcin.2024.09.059.
• [14]Kawakami S,Takahashi A,Taniguchi N,et al.Physiological scaffold remodeling in the coronary artery after 30 months of bioadaptor implantation[J].JACC Case Rep,2025,30(5):103089.DOI:10.1016/j.jaccas.2024.103089.
• [15]Verheye S,Vrolix M,Montorfano M,et al.Twelve-month clinical and imaging outcomes of the uncaging coronary DynamX bioadaptor system[J].EuroIntervention,2020,16(12):e974-e981. DOI:10.4244/EIJ-D-20-00763.
• [16]Verheye S,Morice MC,Zivelonghi C,et al.24-month clinical follow-up and mechanistic insights from intravascular imaging following coronary implantation of the novel DynamX Bioadaptor platform[J].Cardiovasc Revasc Med,2023,46:106-112.DOI:10.1016/j.carrev.2022.09.009.
• [17]Verheye S,Vrolix M,Montorfano M,et al.Final 36-month outcomes from the multicenter DynamX study evaluating a novel thin-strut novolimus-eluting coronary bioadaptor system and supporting preclinical data[J].Rev Cardiovasc Med,2023,24(8):221.DOI:10.31083/j.rcm2408221.
• [18]Leone PP,Mangieri A,Calamita G,et al.DynamX Bioadaptor implantation for treatment of complex coronary artery disease:the DYNAMITE study[J].Am J Cardiol,2026,267:84-92.DOI:10.1016/j.amjcard.2026.02.051.
• [19]Saito S,Bennett J,Nef HM,et al.Percutaneous coronary treatment with bioadaptor implant vs drug-eluting stent:2-year outcomes from BIOADAPTOR RCT[J].JACC Cardiovasc Interv,2025,18(8):988-997. DOI:10.1016/j.jcin.2025.01.426.
• [20]Tsai CH,Chu HH,Huang CC,et al.Dynamic change of coronary artery geometry after bioadaptor implantation:a single-blind randomized controlled trial[J].Circ Cardiovasc Interv,2026,19(2):e016191.DOI:10.1161/CIRCINTERVENTIONS.125.016191.